1. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. (November 2018) Authors: Veenstra, V.; Damhofer, H.; Waasdorp, C.; Rijssen, L.; Vijver, M.; Dijk, F.; Wilmink, H.; Besselink, M.; Busch, O.; Chang, D.; Bailey, P.; Biankin, A.; Kocher, H.; Medema, J.; Li, J.; Jiang, R.; Pierce, D.; Laarhoven, H.; Bijlsma, M. Journal: Oncogenesis Issue: Volume 7(2018:Nov.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Establishing a non-human primate model of osteoarthritis using translational endpoints. (April 2015) Authors: Wald, M.; Chandran, P.; Tao, G.; Tang, R.; Conlon, D.; Sampson, E.; Honore, M.; Kamath, R.; Wang, S.; Medema, J.; Li, J.; Fox, G.; Luo, Y. Journal: Osteoarthritis and cartilage Issue: Volume 23(2015)Supplement 2 Page Start: A211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Health related quality of life among patients with erosive hand osteoarthritis in The United States. (April 2016) Authors: Bodhani, A.R.; Suryavanshi, M.; Medema, J.; Fuldeore, M. Journal: Osteoarthritis and cartilage Issue: Volume 24(2016)Supplement 1 Page Start: S238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of erosive hand osteoarthritis on work productivity among patients in The United States. (April 2016) Authors: Bodhani, A.R.; Suryavanshi, M.; Medema, J.; Fuldeore, M. Journal: Osteoarthritis and cartilage Issue: Volume 24(2016)Supplement 1 Page Start: S234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0447 Safety, Tolerability and Pharmacokinetics of Abt-981, an IL-1A and IL-1β Dual Target Biologic Drug in Development for Osteoarthritis, following Single Dose Administration in Healthy Subjects. (10th June 2014) Authors: Goss, S.; Wang, S.; Klein, C.; Medema, J.; Awni, W. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 755 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial. (12th June 2018) Authors: Fleischmann, R.; Bliddal, H.; Blanco, F.; Schnitzer, T.; Peterfy, C.; Chen, S.; Wang, L.; Conaghan, P.; Berenbaum, F.; Pelletier, J.-P.; Martel-Pelletier, J.; Vaeterlein, O.; Liu, W.; Levy, G.; Zhang, L.; Medema, J.; Levesque, M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0576 Biomarkers predictive of pain improvement in knee osteoarthritis subjects treated with the anti-il-1 alpha/beta dual variable domain immunoglobulin lutikizumab (ABT-981). (12th June 2018) Authors: Feng, S.; Chen, S.; Wang, L.; Peterfy, C.; Kraus, V.; Kamath, R.; Zhang, L.; Luo, Y.; Cui, L.; Medema, J.; Levesque, M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Statistical simulation using data from the foundation for the national institute of health/osteoarthritis initiative biomarkers consortium to evaluate the clinical utility of prognostic knee osteoarthritis biomarkers in designing a knee osteoarthritis clinical trial. (April 2017) Authors: Feng, S.; Liu, Z.; Hong, F.; Medema, J.; Kamath, R.; Levesque, M. Journal: Osteoarthritis and cartilage Issue: Volume 25(2017)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus. (15th July 2016) Authors: Lu, P.; Fleischmann, R.; Curtis, C.; Ignatenko, S.; Desai, M.; Wong, S.L.; Grebe, K.M.; Zeng, J.; Medema, J.; Stolzenbach, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗